Company: SION
Filing Date: 2025-02-03
Form Type: S-1/A
Source: 0001193125-25-018825
Chunk: 285

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-02-03
Form: S-1/A
Chunk 285
---
) 719,355 shares of common stock issuable upon the conversion of Series Seed preferred stock held by                                                                                                                                       
 Atlas Venture Fund XI, L.P. (“AVF XI”), (ii) 1,236,271 shares of common stock issuable upon the conversion of Series A preferred stock held by AVF XI, (iii) 888,599 shares of common stock issuable upon the conversion of Series B                     
 preferred stock held by AVF XI, (iv) 42,068 shares of common stock issuable upon the conversion of Series C preferred stock held by AVF XI, and (v) 747,727 shares of common stock issuable upon the conversion of Series C preferred stock              
 held by Atlas Venture Opportunity Fund II, L.P. (“AVOF II”). Atlas Venture Associates XI, L.P. is the general partner of AVF XI and Atlas Venture Associates XI, LLC is the general partner of Atlas Venture Associates XI, L.P. The members of          
 Atlas Venture Associates XI, LLC collectively make investment decisions on behalf of Atlas Venture Fund XI, LLC. Bruce Booth is a member of Atlas Venture Associates XI, LLC and a member of our board of directors. Each of AVF XI, Atlas Venture       
 Associates XI, L.P. and Atlas Venture Associates XI, LLC may be deemed to beneficially own the shares held by AVF XI. Dr. Booth expressly disclaims beneficial ownership of the shares owned by AVF XI, except to the extent of his pecuniary            
 interest therein, if any. Atlas Venture Associates Opportunity II, L.P. is the general partner of AVOF II, and Atlas Venture Associates Opportunity II, LLC is the general partner of Atlas Venture Associates Opportunity II, L.P. The members of Atlas 
 Venture Associates Opportunity II, LLC collectively make investment decisions on behalf of Atlas Venture Associates Opportunity II, LLC. Dr. Booth is a member of Atlas Venture Associates Opportunity II, LLC. Each of AVOF II, Atlas Venture           
 Associates Opportunity II, L.P., and Atlas Venture Associates Opportunity II, LLC may be deemed to beneficially own the shares held by AVOF II. Dr. Booth expressly disclaims beneficial ownership of the shares owned by AVOF II, except to the         
 extent of his pecuniary interest therein, if any. The address for each of these entities and individuals is 300 Technology Square, 8th Floor, Cambridge, MA 02139.                                                                                       |

| (2) | Consists of (i) 1,